We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Align Technology Banks on Global Growth, Competition Rife
Read MoreHide Full Article
On Feb 1, we issued an updated research report on Align Technology, Inc. (ALGN - Free Report) . The stock carries a Zacks Rank #3 (Hold).
Notably, Align Technology manufactures and markets clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and manufacturing) digital services used in dentistry, orthodontics and dental records storage.
Shares of the company have been trading above its industry over the last year. The stock has rallied 158.8% compared with the industry’s 16.7% growth. The company delivered an encouraging performance in the fourth quarter of 2017, posting better-than-expected earnings and revenues.
We are encouraged by the company’s solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific. The company has witnessed year-over-year growth in both the segments. Also, expansion in gross and operating margin buoys optimism.
We are also upbeat about the company’s distribution agreement with Glidewell Dental to distribute the iTero Element intraoral scanning system with the latest glidewell.io In-Office Solution in North America.
On the flip side, adverse foreign exchange translation continues to raise concerns for Align Technology’s international operations. Also, escalating costs and expenses are weighing on margins. Moreover, a tough competitive landscape and other macroeconomic headwinds pose a threat.
Key Picks
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , ResMed (RMD - Free Report) and PerkinElmer .
ResMed has a Zacks Rank #2. The company has a long-term expected earnings growth rate of 13%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Align Technology Banks on Global Growth, Competition Rife
On Feb 1, we issued an updated research report on Align Technology, Inc. (ALGN - Free Report) . The stock carries a Zacks Rank #3 (Hold).
Notably, Align Technology manufactures and markets clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and manufacturing) digital services used in dentistry, orthodontics and dental records storage.
Shares of the company have been trading above its industry over the last year. The stock has rallied 158.8% compared with the industry’s 16.7% growth. The company delivered an encouraging performance in the fourth quarter of 2017, posting better-than-expected earnings and revenues.
We are encouraged by the company’s solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific. The company has witnessed year-over-year growth in both the segments. Also, expansion in gross and operating margin buoys optimism.
We are also upbeat about the company’s distribution agreement with Glidewell Dental to distribute the iTero Element intraoral scanning system with the latest glidewell.io In-Office Solution in North America.
On the flip side, adverse foreign exchange translation continues to raise concerns for Align Technology’s international operations. Also, escalating costs and expenses are weighing on margins. Moreover, a tough competitive landscape and other macroeconomic headwinds pose a threat.
Key Picks
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , ResMed (RMD - Free Report) and PerkinElmer .
Bio-Rad Laboratories has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The company has a long-term expected earnings growth rate of 25%.
ResMed has a Zacks Rank #2. The company has a long-term expected earnings growth rate of 13%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>